Rigetti (RGTI) Q2 2026 Earnings Call Transcript

Rigetti reported Q2 2026 revenue of $5.1M (vs. $1.8M a year earlier), with gross margin improving to 43% from 31% on improved contract mix/pricing and Novera QPU sales. Non-GAAP net loss narrowed to $16.0M ($0.05/share) from $13.3M ($0.04/share), while cash and investments were $541.3M and the company reiterated no debt, citing sufficient runway despite higher operating expenses of $30.3M. On the business momentum side, it secured a non-definitive potential Department of Commerce CHIPS Act funding commitment of up to $100M over three years and highlighted progress on its 108-qubit Cepheus-1-108Q system (median ~99.1% 2-qubit gate fidelity, ~60ns gate speed), with C-DAC order value of $8.4M expected to recognize in Q4 2026.

Analysis

The near-term setup is mostly a sentiment trade, not a fundamental inflection. The CHIPS-related funding narrative lowers financing risk, but the structure matters more than the headline: if the eventual agreement includes meaningful equity issuance, some of the apparent de-risking gets recycled into dilution. The real signal is that Rigetti is still early in the transition from “interesting hardware” to repeatable system economics; until fidelity gains show up in the 108Q cloud instance, the market is paying for roadmap optionality rather than earnings power.

Relative winners are HPE and, to a lesser extent, cloud distribution partners like AMZN and MSFT, because the hybrid-HPC story strengthens their role as orchestration layers around scarce quantum hardware. The bigger second-order winner may be the superconducting supply chain: any sustained ramp implies more demand for cryogenics, control electronics, and fabrication tooling, but that benefit is scattered and later-cycle. On the other side, non-superconducting quantum peers are vulnerable to a quality-vs-hype comparison if Rigetti keeps shipping real systems above 100 qubits; that said, the comparison only matters if customers care more about accessible uptime and fidelity than modality branding.

The contrarian view is that the market is still over-indexing qubit count and government optics while underweighting the limiting variable: coherence. A 1,000-qubit target in ~3 years is not the same thing as a commercially useful machine, and the path there likely requires higher capex, more experimentation, and potentially more dilution than bulls assume. The key falsifiers are simple: no meaningful 108Q fidelity improvement by year-end, the CHIPS LOI stalls or becomes equity-heavy, or the 2027 HPE/PSC deployment slips; any of those would turn today’s optimism into another financing-and-roadmap overhang.

Key Decisions for Investors

• Trade the event, not the story: buy RGTI only on post-earnings/LOI pullbacks, sized small, with a 1-3 month horizon into the year-end 108Q fidelity update and CHIPS definitive-agreement milestone; thesis fails if no visible 108Q improvement or if LOI terms imply heavy dilution.
• Use options for defined risk: RGTI call spread expiring after the next roadmap update captures upside if the market starts pricing a real technical step-up, while capping downside if the government funding turns into a slow, equity-dilutive process.
• Relative-value idea: long RGTI / short a speculative quantum basket proxy such as QUBT on any sector rally; the spread favors the name with an actual >100-qubit deployed system and clearer government validation, but exit if QUBT gets a materially better funding or commercial catalyst.
• Overweight HPE on the hybrid-HPC angle as a lower-beta beneficiary; the revenue contribution is likely immaterial near term, but the partnership expands HPE’s strategic relevance in emerging AI/HPC workflows. Invalidated if the collaboration remains purely demonstrational and fails to turn into broader enterprise workloads.
• Set a watch item, not a trade alert, on the CHIPS structure and any equity issuance language; if the effective financing price is generous to the government or requires sizable stock issuance, reduce RGTI exposure because the market will likely re-rate the story from 'funded innovation' to 'funded dilution.'